To include your compound in the COVID-19 Resource Center, submit it here.

EpiGenesis, Chiesi, Taisho Pharmaceuticals Co. Ltd. deal

EpiGenesis granted Taisho exclusive rights in Asia to its EPI-2010 antisense oligonucleotide against

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE